Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial

[1]  Lesley Fallowfield,et al.  Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Loi,et al.  PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Vij,et al.  Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma , 2015, Leukemia & lymphoma.

[4]  S. Knudsen,et al.  Development and Validation of a Gene Expression Score That Predicts Response to Fulvestrant in Breast Cancer Patients , 2014, PloS one.

[5]  Gang Han,et al.  Improved survival modeling in cancer research using a reduced piecewise exponential approach , 2014, Statistics in medicine.

[6]  Didier Verhoeven,et al.  Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial , 2013, Journal of the National Cancer Institute.

[7]  F. Cardoso,et al.  A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. , 2013, Cancer treatment reviews.

[8]  Bohuslav Melichar,et al.  Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Hahn,et al.  Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. , 2012, Blood.

[10]  Michael J Schell,et al.  Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test , 2012, Statistics in biopharmaceutical research.

[11]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[12]  P. Boya,et al.  Autophagy promotes survival of retinal ganglion cells after optic nerve axotomy in mice , 2011, Cell Death and Differentiation.

[13]  L. Papa,et al.  Bortezomib Enhances the Efficacy of Fulvestrant by Amplifying the Aggregation of the Estrogen Receptor, Which Leads to a Proapoptotic Unfolded Protein Response , 2011, Clinical Cancer Research.

[14]  M. Boccadoro,et al.  Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. , 2010, Blood.

[15]  M. Lichinitser,et al.  Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Neven,et al.  Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) , 2010, Breast Cancer Research and Treatment.

[17]  P. V. van Dam,et al.  A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Cannistra,et al.  Phase II trials in journal of clinical oncology. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Larry Rubinstein,et al.  Randomized Phase II Designs , 2009, Clinical Cancer Research.

[20]  S. Chen‐Kiang,et al.  A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. , 2008, Cancer research.

[21]  D. Germain,et al.  Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. , 2008, Cancer research.

[22]  Boris Freidlin,et al.  Proposal for the use of progression-free survival in unblinded randomized trials. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. V. Von Roenn,et al.  A Phase II Study of Single Agent Bortezomib in Patients with Metastatic Breast Cancer: A Single Institution Experience , 2007, Cancer investigation.

[24]  D. Esseltine,et al.  Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Anthony Howell,et al.  Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Howell,et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C K Osborne,et al.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Johnston,et al.  Treatment algorithms for hormone receptor-positive advanced breast cancer: going forward in endocrine therapy—overcoming resistance and introducing new agents. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[29]  D. Crivellari,et al.  A Single-Institution Experience , 2013 .

[30]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.